Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
6 Weeks to 12 Weeks (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy infants 6 and 12 weeks of age at the time of the first vaccination.
Written informed consent obtained from the parents or guardians of the subject.
Born after a normal gestation period (between 36 and 42 weeks).
Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the study vaccine or placebo or planned use during the study period.
Chronic administration of immunosuppressants or other immune-modifying drugs since birth. (Topical steroids are allowed.)
Use of antibiotics during the period starting from 7 days before each dose of vaccine(s) and ending 7 days after.
Any clinically significant history of chronic gastrointestinal disease or other serious medical condition as determined by the investigator.
Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.
Gastroenteritis within 7 days preceding the study vaccine administration (warrants deferral of the vaccination).
Household contact with an immunosuppressed individual or pregnant woman.
Abnormal stool pattern.
Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.
Previous confirmed occurrence of rotavirus gastroenteritis.
Soriano-Gabarró M et al. (2008) Potential impact of Rotarix according to rotavirus type distribution. Pediatr Infect Dis J. 27(1):28-32.
Vesikari T et al. (2003) Efficacy of oral human rotavirus vaccine in infants against acute rotavirus gastroenteritis in the community determined with rotavirus antigen detection by EIA and rotavirus RT-PCR as end points. J Clin Virol. 27(1):8 (Abstract n° 24).